WallStreetZenWallStreetZen

NASDAQ: OTLK
Outlook Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for OTLK

Based on 3 analysts offering 12 month price targets for Outlook Therapeutics Inc

Min Forecast
$1.60+208.29%
Avg Forecast
$5.37+934.1%
Max Forecast
$10.50+1,923.12%

Should I buy or sell OTLK stock?

Based on 3 analysts offering ratings for Outlook Therapeutics Inc.

Buy
Strong Buy
1 analysts 33.33%
Buy
1 analysts 33.33%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although OTLK's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates OTLK as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their OTLK stock forecasts and price targets.

OTLK stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-11
lockedlocked$00.00+00.00%2026-08-14
lockedlocked$00.00+00.00%2026-07-27

1 of 1

Forecast return on equity

Is OTLK forecast to generate an efficient return?

Company
-1,314.15%
Industry
22.83%
Market
178.37%
OTLK's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is OTLK forecast to generate an efficient return on assets?

Company
521.58%
Industry
23.31%
OTLK is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

OTLK earnings per share forecast

What is OTLK's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.12
Avg 2 year Forecast
$0.34
Avg 3 year Forecast
$0.56

OTLK revenue forecast

What is OTLK's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$46.9M
Avg 2 year Forecast
$174.1M
Avg 3 year Forecast
$268.2M

OTLK vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
OTLK$0.52$5.37+934.10%Buy
NKTX$1.79$11.67+551.79%Strong Buy
AVXL$1.33N/AN/A
SPRB$45.15$140.29+210.71%Strong Buy
HUMA$0.44$5.63+1,193.10%Strong Buy
View Top Biotech Stocks

Outlook Therapeutics Stock Forecast FAQ

Is Outlook Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: OTLK) stock is to Buy OTLK stock.

Out of 3 analysts, 1 (33.33%) are recommending OTLK as a Strong Buy, 1 (33.33%) are recommending OTLK as a Buy, 1 (33.33%) are recommending OTLK as a Hold, 0 (0%) are recommending OTLK as a Sell, and 0 (0%) are recommending OTLK as a Strong Sell.

If you're new to stock investing, here's how to buy Outlook Therapeutics stock.

What is OTLK's earnings growth forecast for 2027-2029?

(NASDAQ: OTLK) Outlook Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.7%.

Outlook Therapeutics's earnings in 2026 is -$61,123,257.On average, 6 Wall Street analysts forecast OTLK's earnings for 2027 to be -$29,797,981, with the lowest OTLK earnings forecast at -$64,416,223, and the highest OTLK earnings forecast at -$7,668,598. On average, 4 Wall Street analysts forecast OTLK's earnings for 2028 to be $81,944,447, with the lowest OTLK earnings forecast at $21,472,074, and the highest OTLK earnings forecast at $145,703,361.

In 2029, OTLK is forecast to generate $136,574,078 in earnings, with the lowest earnings forecast at $35,786,790 and the highest earnings forecast at $242,838,935.

What is OTLK's revenue growth forecast for 2027-2029?

(NASDAQ: OTLK) Outlook Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.1%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.16%.

Outlook Therapeutics's revenue in 2026 is -$1,163,481.On average, 6 Wall Street analysts forecast OTLK's revenue for 2027 to be $11,427,671,632, with the lowest OTLK revenue forecast at $7,157,358,088, and the highest OTLK revenue forecast at $19,105,520,590. On average, 4 Wall Street analysts forecast OTLK's revenue for 2028 to be $42,376,915,725, with the lowest OTLK revenue forecast at $17,489,272,279, and the highest OTLK revenue forecast at $68,506,141,696.

In 2029, OTLK is forecast to generate $65,292,633,983 in revenue, with the lowest revenue forecast at $23,350,515,589 and the highest revenue forecast at $109,405,330,768.

What is OTLK's forecast return on assets (ROA) for 2027-2029?

(NASDAQ: OTLK) forecast ROA is 521.58%, which is higher than the forecast US Biotechnology industry average of 23.31%.

What is OTLK's Price Target?

According to 3 Wall Street analysts that have issued a 1 year OTLK price target, the average OTLK price target is $5.37, with the highest OTLK stock price forecast at $10.50 and the lowest OTLK stock price forecast at $1.60.

On average, Wall Street analysts predict that Outlook Therapeutics's share price could reach $5.37 by Sep 11, 2027. The average Outlook Therapeutics stock price prediction forecasts a potential upside of 934.1% from the current OTLK share price of $0.52.

What is OTLK's Earnings Per Share (EPS) forecast for 2027-2029?

(NASDAQ: OTLK) Outlook Therapeutics's current Earnings Per Share (EPS) is -$0.77. On average, analysts forecast that OTLK's EPS will be -$0.12 for 2027, with the lowest EPS forecast at -$0.26, and the highest EPS forecast at -$0.03. On average, analysts forecast that OTLK's EPS will be $0.34 for 2028, with the lowest EPS forecast at $0.09, and the highest EPS forecast at $0.60. In 2029, OTLK's EPS is forecast to hit $0.56 (min: $0.15, max: $1.00).

What is OTLK's forecast return on equity (ROE) for 2027-2029?

(NASDAQ: OTLK) forecast ROE is -1,314.15%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.